Head-to-head · WeighScore
Ro vs bmiMD
The verdict
bmiMD takes it — 84/100 to 78/100.
bmiMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Among the cheapest both-molecule pairings ($99/$139), nationwide — but not LegitScript-listed.
Both are editorial reviews with no commercial relationship.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Ro | bmiMD |
|---|---|---|
| WeighScore | 78/100 | 84/100 |
| Grade | C+ | B |
| Scorecard rank | #24 | #16 |
| Semaglutide | Not disclosed | $99/mo |
| Tirzepatide | Not disclosed | $139/mo |
| Coverage | Multi-state | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
| Relationship | Editorial | Editorial |
Graded #24 · C+
Strengths
- Brand-name access + insurance support
- Oral options
- Well-funded platform
Where it loses points
- Does not disclose compounded pricing up front
- Premium positioning
Graded #16 · B
Strengths
- $99 sema / $139 tirz
- All 50 states
- Both molecules
Where it loses points
- Not LegitScript-verified
- Injection-only
- Thin oversight/monitoring detail
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.